Trial Profile

A Phase 1 Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With Muscle Invasive Bladder Cancer (MIBC)

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 10 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cretostimogene grenadenorepvec (Primary) ; Nivolumab (Primary) ; Anti-CTLA-4 monoclonal antibody
Indications Bladder cancer
Focus Adverse reactions; Therapeutic Use
Acronyms CORE2; NAOMI

Most Recent Events

06 Feb 2025 Planned End Date changed from 1 Feb 2025 to 1 Jan 2026.
11 Nov 2024 Results presented in the CG Oncolgy Media Release.
11 Nov 2024 According to a CG Oncolgy media release, Phase 1b study results were published simultaneously in Nature Medicine and presented at the Society for Immunotherapy of Cancer 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com